$155,800
median · per year, annualized USD
$103,325
median · per year, annualized USD
Clinical Trial Reimbursement (CTR) Senior Manager, HE&R
Senior Clinical Trial Manager - Oncology
Senior Clinical Trial Manager - Cardiovascular, CAR-T
Senior Clinical Trial Manager - Psychiatry
Senior Clinical Trial Manager - Oncology - U.S.
Senior Clinical Trial Manager - Metabolic
Sr Manager, Technical Operations - Clinical Trial Capabilities
Trial Master File Sr. Manager, Clinical Operations
Sr. Clinical Trial Manager, Therapeutics and Oncology
Clinical Trial Manager/Senior Clinical Trial Manager
Senior Specialist I, Postmarketing Patient Safety and Pharmacovigilance Operations
Senior Medical Officer-Infectious Diseases & Pharmacovigilance
Pharmacovigilance QA Auditor Specialist
Pharmacovigilance Specialist - US - Remote
Drug Safety Associate - Bilingual - French - 12-Month Contract
| Company | Median | Roles |
|---|---|---|
| WC Worldwide Clinical Trials | $167,000 | 5 |
IQVIA
|
$137,400 | 4 |
St Vincent's Health Australia
|
$95,079 | 3 |
Corcept Therapeutics
|
$178,025 | 2 |
Eikon Therapeutics
|
$158,125 | 2 |
Moderna
|
$156,000 | 2 |
| BI Biogen | $150,750 | 2 |
Abbott
|
$143,500 | 2 |
| Company | Median | Roles |
|---|---|---|
Corcept Therapeutics
|
$140,850 | 1 |
| GU Guidehouse | $113,000 | 1 |
Johnson & Johnson
|
$103,325 | 1 |
| WC Worldwide Clinical Trials | $74,500 | 1 |
Cencora
|
$31,298 | 1 |
| Location | Median | Roles |
|---|---|---|
| San Francisco | $156,000 | 3 |
| Boston | $135,000 | 5 |
The median for Clinical Trial is $155,800 per year (typically $120,438–$167,000), versus $103,325 for Pharmacovigilance ($74,500–$113,000). That puts Clinical Trial about 51% ahead at the median.
Both figures are computed live from active listings on JobsRadar and normalized to annualized USD, so Clinical Trial and Pharmacovigilance are compared on equal terms regardless of the currency each role was originally posted in. Only roles that publish a salary range feed the medians; numbers refresh every few hours as new roles post and older ones close, so this comparison reflects the market right now rather than a fixed survey. Use it as a directional benchmark when weighing one path against the other.